Koike N, Ohwada S, Ogawa T, Kawashima K, Takeyoshi I, Sato Y, Kamiyama H, Morishita Y
Second Dept. of Surgery, Gunma University School of Medicine.
Gan To Kagaku Ryoho. 1998 May;25(6):919-23.
An advanced gastric cancer patient with T3N1M0 successfully underwent a curatively total gastrectomy combined with distal pancreatectomy and lymphnode dissection following ELF-P combined chemotherapy. The patient received two courses of etoposide (75 mg/m2, Day 1-5, i.v.), leucovorin (30 mg/body, Day 2-5, i.v.), 5-FU (500 mg/m2, Day 2-5, i.v.) and CDDP (60 mg/m2, Day 1, i.v.). A partial response for the primary lesion and lymphnode metastasis was obtained, and a successful curative resection of the stomach was performed. No drug adverse responses occurred. The effect of ELF-P chemotherapy was confirmed with grade 1b by histopathological examinations. Neoadjuvant chemotherapy with ELF-P may be useful as an inductive approach for advanced gastric cancer.
一名T3N1M0期进展期胃癌患者在接受ELF-P联合化疗后，成功接受了根治性全胃切除术联合远端胰腺切除术及淋巴结清扫术。患者接受了两个疗程的依托泊苷（75mg/m²，第1 - 5天，静脉注射）、亚叶酸钙（30mg/体，第2 - 5天，静脉注射）、5-氟尿嘧啶（500mg/m²，第2 - 5天，静脉注射）和顺铂（60mg/m²，第1天，静脉注射）治疗。对原发灶和淋巴结转移获得了部分缓解，并成功进行了胃癌根治性切除。未发生药物不良反应。通过组织病理学检查证实ELF-P化疗效果为1b级。ELF-P新辅助化疗可能作为进展期胃癌的一种诱导治疗方法是有用的。
